title: Comment.
authors.forename: A
authors.initials: A
authors.lastname: Furedi
mesh_terms: D000019:Abortifacient Agents; D000028:Abortion, Induced; D000554:Ambulatory Care Facilities; D001695:Biology; D003695:Delivery of Health Care; D019049:Developed Countries; D004703:Endocrine System; D004739:England; D005060:Europe; D005193:Family Planning Services; D006262:Health; D006268:Health Facilities; D006297:Health Services Accessibility; D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone; D010827:Physiology; D015397:Program Evaluation; D006113:United Kingdom
chemical_list: D000019:Abortifacient Agents; D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
keywords: Abortifacient Agents; Abortion Centers; Abortion, Drug Induced; Abortion, Induced; Biology; Delivery Of Health Care; Developed Countries; Endocrine System; England; Europe; Family Planning; Fertility Control, Postconception; Health; Health Facilities; Hormone Antagonists; Hormones; Northern Europe; Physiology; Program Accessibility; Program Evaluation; Programs; Ru-486; United Kingdom